LITESPARK 6482-013
This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
CLINICALTRIALS.GOV IDENTIFIER:
NCT04489771
When speaking to your doctor, please have the trial identifier number available.
All participants who enroll in the trial are receiving investigational medication. All participants in this trial will get MK-6482. How much of the drug you get will depend on which group you are placed in.*
50% will get 120 mg of MK-6482 each day
50% will get 200 mg of MK-6482 each day
*A computer will decide which group you are put in. You have an equal chance of getting put in either group. You, your trial doctor, and the trial staff will know what dose of MK-6482 you are getting.
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Dates
Conditions
Carcinoma, Renal Cell
Age Range
18 - No Age Maximum
Sex
All
If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.
Print this page or email it to your doctor to discuss at your next visit.
CLINICALTRIALS.GOV IDENTIFIER:
NCT04489771
When speaking to your doctor, please have the trial identifier number available.
Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
Print this page
Email this page